Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Abstract Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK‐positive NSCLCs. However, the emergence of acquired resistance is inevitable. In this study, we investigated the drugs fo...

Full description

Bibliographic Details
Main Authors: Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Thoracic Cancer
Subjects:
ALK compound mutation
next‐generation sequence
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13299

Internet

https://doi.org/10.1111/1759-7714.13299

Similar Items